Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Open-But-Unused SUD Reprocessing Will Not Be Pursued - FDA's Kessler

This article was originally published in The Gray Sheet

Executive Summary

FDA expects to issue a final guidance by August on its approach to regulate reprocessing of single-use devices (SUDs) by third-party facilities, according to Larry Kessler, director of the Center for Devices and Radiological Health's Office of Surveillance and Biometrics.

You may also be interested in...



OEMs, FDA Still At Odds Over Premarket Requirements For Reprocessed SUDs

It appears unlikely that FDA will require all reprocessor submissions for single-use devices to support a "reusable" claim, despite opposing comments by Smith & Nephew and other original equipment manufacturers.

OEMs, FDA Still At Odds Over Premarket Requirements For Reprocessed SUDs

It appears unlikely that FDA will require all reprocessor submissions for single-use devices to support a "reusable" claim, despite opposing comments by Smith & Nephew and other original equipment manufacturers.

Reprocessors, OEMs Will Operate On "Level Playing Field," Feigal Testifies

FDA Center for Devices and Radiological Health Director David Feigal promised the House Commerce/ Oversight and Investigations Subcommittee Feb. 10 that new regulations on reuse of single-use devices will be equally applied to manufacturers and reprocessors.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT013438

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel